<DOC>
	<DOCNO>NCT00356616</DOCNO>
	<brief_summary>To evaluate whether combined therapy two nucleoside plus one nucleotide ( Trizivir + TDF ) manage keep CD4 lymphocytes stable patient HIV infection antiretroviral treatment present virological failure multiple resistance antiretrovirals .</brief_summary>
	<brief_title>Immuno-Virological Efficacy Combination With Trizivir +Tenofovir Multiresistant HIV Patients</brief_title>
	<detailed_description>This study design determine whether use regimen base exclusively NTRI , contain tenofovir , zidovudine lamivudine , able preserve immunological status patient detectable viral load efficacious salvage regimen design , slow progression viral load reduce antiretroviral treatment-associated toxicity . In order complete salvage regimen without increase number tablet much , Trizivir plus tenofovir investigational treatment use .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>1 . Age &gt; = 18 year . 2 . HIV1 infect patient . 3 . Patients antiretroviral treatment include NTRI + PI +/ NNRTI +/ fusion inhibitor inclusion study . 4 . Virological failure , define 2 determination viral load &gt; 1,000 copies/mL last 6 month , stable HAART therapy previous 6 month . 5 . Genotype phenotype resistance three family antiretrovirals ( PI , NTRI NNRTI ) demonstrate genotype study carry last 48 week define : 3 TAMS follow : M41L , E44D , D67N , V118I , L210W , T215Y/F , K219Q/E . Existence M184V mutation probable presence cellular archive . 5 mutation confer resistance PI following : I10F/I/R/V , V32I , M46I/L , I54V/M/L , V82A/F/T/S/V , I84V/A/C , L90M . Existence 1 mutation confer resistance NNRTI , probable presence cellular archive : K103N , Y181C/I/Y , G190S/A/G . 6 . CD4 lymphocytes &gt; 300 cells/mm3 last two determination . 7 . Subject able follow treatment period . 8 . Acceptance study signature inform consent form . 9 . Women may fertile age ( define least one year menopause undergoing surgical sterilisation technique ) , must undertake use barrier contraceptive method study . Suspicion previous incorrect adherence . Pregnancy breastfeed Suspicion intolerance investigational drug . Record disease , accord clinical criterion , may reoccur propose change therapy ( sarcoma , lymphoma , etc ) . CD4 Nadir 200 cel/mm3 . Acute intercurrent disease fever 15 day inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Antiretroviral treatment</keyword>
	<keyword>virological failure</keyword>
	<keyword>HIV</keyword>
</DOC>